Anupco


ANFLOX FEED PREMIX

Feed premix

COMPOSITION

Norfloxacin 100 mg- Excipients up to 1g.

PHARMACOLOGICAL PROPERTIES

Norfloxacin has potent antimicrobial activities against many pathogens, including E. coli, Staphylococcus spp., Pseudomonas aeruginosa and Mycoplasma gallisepticum. Norfloxacin is well absorbed orally. Peak serum concentrations are reached 20 minutes post-dosing, with an elimination t 1/2 of 12 hours and a bioavailability of 57 %. Norfloxacin tends to penetrate the tissues rather slowly, with peak concentrations appearing 8 hours after dosing for all tissues except fat, where peak concentrations are reached at 24 hours after the oral dose. Norfloxacin is metabolized by the liver and excreted primarily in the urine. The elimination t 1/2 for a single IV dose is approximately 8 hours.

INDICATIONS

Treatment and prevention of infectious diseases caused by Gram-positive, Gram-negative bacteria and Mycoplasmas in poultry and pigs.

CONTRA-INDICATIONS

Hypersensitivity to norfloxacin and other quinolone group antibiotics is contra-indicated.

DOSAGE AND MODE OF ADMINISTRATION

Incorporate in finished feed at the following levels (accurate mixing is essential):

- Poultry: 0.50-0.75 kg per tonne

- Pigs: 1.00-1.50 kg per tonne

Use higher levels in cases of severe infection and for the control of salmonella. Medicated feed should be given for 5-7 days (7-10 days for the control of salmonella).

UNDESIRABLE EFFECTS

Arthropathies are reported in laboratory animals following norfloxacin treatment. In poultry these effects have not been seen, probably because doses were not high enough to induce an arthropathy.

SPECIAL PRECAUTIONS AND WARNINGS

ANFLOX FEED PREMIXámay also be used without any reaction or toxicity effect at the same time as other feed additives such as growth promoters or anticoccidials. There is no adverse reaction between it and ionophores (e.g. Monensin).

PACK SIZE

10 kg

Please be aware that product specifications and availability can differ between countries. For detailed information in this regard, please contact us.

You are viewing the English version of this website enesfr